Skip to content
2000
Volume 18, Issue 13
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Background: One of the most important causes of death in the modern lifestyle is acute ischemic stroke, which is related to thrombosis in the blood vessels. Staphylokinase (SAK), a fibrinolytic agent, which is produced mainly by Staphylococcus aureus, is an indirect activator of plasminogen and belongs to the third generation of fibrinolytic enzymes. Methods: Considering the very low level of production and immunogenicity concerns of natural SAK produced by Staphylococcus aureus, attempts have been made to produce recombinant SAKs with high production levels, more fibrinolytic activities and low immunogenicity. Results and Conclusion: In this review, we summarized a number of expression systems based on recombinant DNA technology and protein-engineering approaches, which have been developed for the production of engineered recombinant SAK molecules with higher fibrinolytic activities and lower antigenicity.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201019666180209121323
2017-11-01
2025-05-30
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201019666180209121323
Loading

  • Article Type:
    Review Article
Keyword(s): fibrinolytics; immunogenicity; plasminogen; recombinant; Staphylokinase; thrombolysis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test